Saskia M. Brachmann - Concepedia

Author

Saskia M. Brachmann

Also Known As

Brachmann, Saskia Maria, S Brachmann, S. M. Brachmann, Saskia Brachmann, Saskia M Brachmann, Saskia M. Brachmann, saskia Brachmann

170

Publications

7.1K

Citations

H-Index

Concepts

All Affiliations

Novartis (Switzerland)Novartis Institutes for BioMedical Research Beth Israel Deaconess Medical Center Freie Universität Berlin Harvard University

About

Saskia M. Brachmann is an author at Novartis (Switzerland) specializing in medicine, cell biology, and signal transduction.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	15	16	3.1K
2	Natural Sciences	7	7	973
3	Health Sciences	4	4	888
4	Engineering	3	3	752
5	Applied Physiology	1	1	15

Saskia M. Brachmann

Publications

6.9K

Citations

H-Index

Page 1

	Year	Citations
Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent <i>in vivo</i> antitumor activity Sauveur-Michel Maira, Frédéric Stauffer, Josef Brueggen, Molecular Cancer Therapeutics	2008	1.1K
Project DRIVE: A Compendium of Cancer Dependencies and Synthetic Lethal Relationships Uncovered by Large-Scale, Deep RNAi Screening E. Robert McDonald, Antoine de Weck, Michael R. Schlabach, Cell BioinformaticsTumor BiologyRadiation OncologyFunctional GenomicsProject Drive	2017	687
Distinct roles of class I and class III phosphatidylinositol 3-kinases in phagosome formation and maturation Otília V. Vieira, Roberto J. Botelho, Lucia E. Rameh, The Journal of Cell Biology	2001	524
Identification and Characterization of NVP-BKM120, an Orally Available Pan-Class I PI3-Kinase Inhibitor Sauveur-Michel Maira, Sabina Pecchi, Alan Huang, Molecular Cancer Therapeutics PharmacotherapyDifferent Selectivity ProfileChemical BiologyPharmaceutical ChemistryTumor Biology	2011	524
Breast Cancer–Associated <i>PIK3CA</i> Mutations Are Oncogenic in Mammary Epithelial Cells Steven J. Isakoff, Jeffrey A. Engelman, Hanna Y. Irie, Cancer Research	2005	490
Characterization of the Novel and Specific PI3Kα Inhibitor NVP-BYL719 and Development of the Patient Stratification Strategy for Clinical Trials Christine Fritsch, Alan Huang, Christian Chatenay‐Rivauday, Molecular Cancer Therapeutics Pten MutationSomatic Pik3ca MutationsPharmacotherapyCancer BiologyTumor Biology	2014	462
Specific apoptosis induction by the dual PI3K/mTor inhibitor NVP-BEZ235 in HER2 amplified and PIK3CA mutant breast cancer cells Saskia M. Brachmann, Irmgard Hofmann, Christian Schnell, Proceedings of the National Academy of Sciences Dual Pi3k/mtor InhibitorBreast OncologyOncologyApoptosis InductionMedicine	2009	316
Molecular Balance between the Regulatory and Catalytic Subunits of Phosphoinositide 3-Kinase Regulates Cell Signaling and Survival Kohjiro Ueki, Saskia M. Brachmann, Yu‐Hua Tseng, Molecular and Cellular Biology	2002	286
Phosphoinositide 3-kinase activates Rac by entering in a complex with Eps8, Abi1, and Sos-1 Metello Innocenti, Emanuela Frittoli, Isabella Ponzanelli, The Journal of Cell Biology	2003	265
Increased insulin sensitivity in mice lacking p85β subunit of phosphoinositide 3-kinase Kohjiro Ueki, Claudine M. Yballe, Saskia M. Brachmann, Proceedings of the National Academy of Sciences P85β SubunitCellular PhysiologyInsulin SignalingClass IaMetabolic Syndrome	2001	234

Page 1